Search Patents
  • Neoantigens and uses thereof
    Patent number: 11793867
    Abstract: Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: October 24, 2023
    Assignee: BIONTECH US INC.
    Inventor: Vikram Juneja
  • Polypeptide comprising a knottin protein moiety
    Publication number: 20100267610
    Abstract: A polypeptide, with an amino acid sequence different from that of knottin protein, having a scaffold moiety with a helix moiety inserted in the scaffold moiety is described. The scaffold moiety comprises a knottin protein, or a fragment of knottin protein.
    Type: Application
    Filed: February 18, 2008
    Publication date: October 21, 2010
    Applicant: BIONTECH AG
    Inventors: Michael Blind, Harald Kolmar
  • Multispecific antibodies against CD40 and CD137
    Patent number: 11084882
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: August 10, 2021
    Assignees: GENMAB A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • Modification of RNA, Producing an Increased Transcript Stability and Translation Efficiency
    Publication number: 20190062762
    Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
    Type: Application
    Filed: September 27, 2018
    Publication date: February 28, 2019
    Applicant: BioNTech AG
    Inventors: Ugur Sahin, Silke Holtkamp, Ozlem Tureci, Sebastian Kreiter
  • Identification of tumor-associated markers for diagnosis and therapy
    Patent number: 10253373
    Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: April 9, 2019
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Methods and kits for the molecular subtyping of tumors
    Patent number: 10808283
    Abstract: The present invention relates to an in vitro method of identifying a molecular subtype of a tumor in a cancer patient and to a method of stratifying a cancer patient for tumor treatment. The present invention further relates to kits that are useful for identifying a molecular subtype of a tumor in a cancer patient.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: October 20, 2020
    Assignees: BioNTech Diagnostics GmbH, STRATIFYER MOLECULAR PATHOLOGY GMBH
    Inventors: Ralph Wirtz, Christoph Kneip
  • Modification of RNA, producing an increased transcript stability and translation efficiency
    Patent number: 10106800
    Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: October 23, 2018
    Assignee: BioNTech AG
    Inventors: Ugur Sahin, Silke Holtkamp, Ozlem Tureci, Sebastian Kreiter
  • AMPHOTERIC LIPOSOMES COMPRISING IMINO LIPIDS
    Publication number: 20200330384
    Abstract: The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are imino moieties that are essentially charged under physiological conditions, and their use for serum resistant transfection of cells.
    Type: Application
    Filed: May 4, 2020
    Publication date: October 22, 2020
    Applicant: BioNTech Delivery Technologies GmbH
    Inventors: Steffen PANZNER, Evgenios SIEPI
  • Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
    Patent number: 11183272
    Abstract: Methods for preparing a personalized cancer vaccine and a method to train a machine-learning HLA-peptide presentation prediction model.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: November 23, 2021
    Assignee: BIONTECH US INC.
    Inventors: Michael Steven Rooney, Jennifer Grace Abelin, Dominik Barthelme, Robert Kamen
  • Modification of RNA, producing an increased transcript stability and translation efficiency
    Patent number: 9476055
    Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: October 25, 2016
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Silke Holtkamp, Özlem Türeci, Sebastian Kreiter
  • RECOMBINANT VACCINES AND USE THEREOF
    Publication number: 20140134201
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 15, 2014
    Applicant: BioNTech AG
    Inventors: Ozlem Tureci, Ugur Sahin, Sebastian Kreiter
  • Coronavirus vaccine
    Patent number: 11878055
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.
    Type: Grant
    Filed: June 26, 2023
    Date of Patent: January 23, 2024
    Assignee: BioNTech SE
    Inventors: Alexander Muik, Kena Anne Swanson, Qi Yang, Hui Cai, Ugur Sahin, Kayvon Modjarrad
  • Carboxylated 2?-amino-LNA nucleotides and oligonucleotides comprising the same
    Patent number: 10894962
    Abstract: The invention proves an oligonucleotide comprising one or more carboxylated 2?-amino-LNA nucleotide units. The invention also provides a method of transfecting cells with the oligonucleotide, a method of treating a human or animal by therapy using the oligonucleotide, and a pharmaceutical composition comprising the oligonucleotide.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: January 19, 2021
    Assignee: BIONTECH DELIVERY TECHNOLOGIES GMBH
    Inventor: Steffen Panzner
  • Compositions and methods for diagnosis and treatment of cancer
    Patent number: 10370433
    Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: August 6, 2019
    Assignee: Biontech AG
    Inventors: Ugur Sahin, Joycelyn Wüstehube-Lausch, Markus Fiedler, Matin Daneschdar, Hans-Ulrich Schmoldt
  • Multispecific antibodies against CD40 and CD137
    Patent number: 11440966
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: September 13, 2022
    Assignees: GENMAB A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • Recombinant Vaccines and Use Thereof
    Publication number: 20180177885
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 28, 2018
    Applicant: BioNTech AG
    Inventors: Ozlem Tureci, Ugur Sahin, Sebastian Kreiter
  • Identification of tumor-associated markers for diagnosing or monitoring ovarian cancer
    Patent number: 9175088
    Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: November 3, 2015
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Methods of producing multispecific antibodies against CD40 and CD137
    Patent number: 11091557
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: August 17, 2021
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • STABLE FORMULATIONS OF LIPIDS AND LIPOSOMES
    Publication number: 20170273907
    Abstract: The present invention related to aqueous lipid and/or liposome formulations with an increased chemical stability, to methods of preparing such aqueous formulations as well as to kits comprising them. The present invention further relates to methods of preparing lipid-based pharmaceutical compositions, to pharmaceutical compositions prepared by such methods and to methods of chemically stabilizing aqueous lipid and/or liposome formulations.
    Type: Application
    Filed: September 17, 2015
    Publication date: September 28, 2017
    Applicant: BioNTech RNA Pharmaceuticals GmbH
    Inventors: Heinrich HAAS, Isaac Hernan ESPARZA BORQUEZ
  • Hydrogen water generator
    Patent number: D885517
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: May 26, 2020
    Assignee: BIONTECH CO., LTD
    Inventor: Kyu Dai Cho
Narrow Results

Filter by US Classification